Avacta Group plc announced that Dr. Jose Saro has been appointed as Chief Medical Officer to lead the Group's therapeutic development strategy and drive the in-house programmes into the clinic. Dr. Saro brings over 20 years' experience in the pre-clinical, translational and early clinical development of oncology assets, spanning small molecules, biologics and drug conjugates. Dr. Saro joins Avacta from Roche where he held the role of Senior Translational Medicine Leader at the Roche Innovation Center Zurich in which he focused on immuno-oncology and the development of combination products.